The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

In total, 169 patients participated in the survey; the majority of the patients stated their general health status as good (72.2%) and excellent (13.6%). Patients who rated their overall health status ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

In a real-world study, only 35% of patients completed the full guideline-recommended 4-6 cycles of chemotherapy as first-line treatment for metastatic bladder cancer. Real-world data show suboptimal ...

Pharmaceutical treatment for urinary tract infections (UTI) is significantly associated with a higher risk for a delayed diagnosis of muscle-invasive or metastatic bladder cancer. Treatment for ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...